Efficacy of Setarud (IMOD<sup>®</sup>), a novel drug with potent anti-toxic stress potential in rat inflammatory bowel disease and comparison with dexamethasone and infliximab
219-226The inflammatory
bowel disease (IBD) is an idiopathic, immune-mediated and chronic intestinal
condition. In the present study, the effect of Serarud (IMOD®), a novel natural
drug with known immunomodulatory, anti-inflammatory and antioxidant properties
was investigated in experimental colitis in rats and compared with the dexamethasone and infliximab.
Immunologic colitis was induced by intracolonic administration of a mixture of
trinitrobenzene sulfonic acid (TNBS) and absolute ethanol in male Wistar rats.
Animals were divided into 6 groups of sham (normal group), control
(vehicle-treated), positive control (dexamethasone 1 mg/kg/day given orally and
infliximab 5 mg/kg/day given subcutaneously) and 3 Setarud-treated
groups (13.3, 20, 30 mg/kg/day given intraperitoneally). The treatment
continued for 14 consecutive days and then animals were decapitated on the day
15 and distal colons were removed for macroscopic, microscopic, and biochemical
assays. Biochemical markers, including TNF-, IL-1, ferric
reducing/antioxidant power (FRAP), myeloperoxidase (MPO) activity and
thiobarbitoric acid-reactive substance (TBARS) were measured in the homogenate
of colonic tissue. A remarkable reduction in macroscopic and histological
damage scores was observed in the animals treated with Setarud. These findings
were confirmed by decreased levels of TNF-, interleukin-1, MPO activity and
TBARS, and raised levels of FRAP in the colon tissue. These observations
confirmed the immunomodulatory, anti-inflammatory and antioxidant properties of
Setarud in experimental colitis, which was comparable to those of dexamethasone
and infliximab